Skip to main content
. 2016 May 12;127(26):3360–3368. doi: 10.1182/blood-2015-11-683854

Table 3.

Grade 3 (or higher) AEs occurring in at least 3% of all patients

AE, n (%) Phase 1 Phase 2
Phase 1-2
45 mg/m2 (n = 3) 56 mg/m2 (n = 3) 70 mg/m2 (n = 15) 88 mg/m2 (n = 6) 70 mg/m2 (n = 89) 70 mg/m2 (n = 104)
Fatigue 0 0 1 (7) 1 (17) 10 (11) 11 (11)
Pneumonia 0 0 1 (7) 0 5 (6) 6 (6)
Acute kidney injury 0 0 0 0 6 (7) 6 (6)
Hypertension 0 0 0 0 7 (8) 7 (7)
Thrombocytopenia 0 0 2 (13) 0 4 (4) 6 (6)
Anemia 0 0 0 0 6 (7) 6 (6)
Asthenia 0 0 0 0 5 (6) 5 (5)
Back pain 0 0 2 (13) 0 3 (3) 5 (5)
COPD 0 0 2 (13) 0 3 (3) 5 (5)
Blood creatinine increased 1 (33) 0 0 0 3 (3) 3 (3)
Congestive cardiac failure 0 0 0 1 (17) 2 (2) 2 (2)
Diarrhea 0 0 0 0 4 (4) 4 (4)
Headache 0 0 1 (7) 1 (17) 2 (2) 3 (3)
Hypokalemia 1 (33) 0 0 0 3 (3) 3 (3)
Hypoxia 0 0 0 0 4 (4) 4 (4)
Neutropenia 0 0 1 (7) 0 3 (3) 4 (4)
Pain in extremity 0 0 1 (7) 0 2 (2) 3 (3)
Upper respiratory tract infection 0 1 (33) 1 (7) 1 (17) 0 1 (1)
Sepsis 0 0 0 0 3 (3) 3 (3)
Dyspnea 0 0 1 (7) 0 4 (4) 5 (5)
Hypophosphatemia 0 0 0 0 3 (3) 3 (3)
Hyperglycemia 0 0 0 1 (17) 2 (2) 2 (2)
Spinal cord compression 0 0 1 (7) 0 2 (2) 3 (3)

COPD, chronic obstructive pulmonary disease.